Biogen Licenses Parkinson’s Drug from Alectos Therapeutics for up to US$722.5 M

By Ashish Tripathi

Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)

Published: 14 Jun-2022

DOI: 10.3833/pdr.v2022.i6.2696     ISSN: 1756-7874

Section: Licensing



In a bid to bolster its pipeline, Biogen has partnered with Alectos Therapeutics to develop and commercialise glucocerebrosidase 2 (GBA2) inhibitors...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details